Study: NCT01738503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.